Q-omics provides the consensus-scored ZNF322 profile across patient tissues and cancer cell-line models. ZNF322 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ZNF322 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZNF322 RNA expression shows 20,409 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, HNSC, and THYM as cancer lineages where ZNF322 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF322 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF322 survival associations across molecular data types. ZNF322 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF322 RNA expression–survival associations across cancer types. High ZNF322 expression shows unfavorable associations in BLCA, but favorable associations in LUAD, KIRC, UCS, READ and THYM. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ZNF322 RNA expression.
This table summarizes ZNF322 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF322. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF322 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LIHC, LUAD and BRCA. The HNSC box plot shows higher ZNF322 RNA expression in tumor versus normal tissue (log2 FC = +0.803, t-test p < 0.001).
This table shows molecular features associated with ZNF322 in patient tissues and cancer cell lines. In patient samples, ZNF322 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF322 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
